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Abstract
Background: Peak oxygen uptake (VO2peak) is a strong predictor of cardiovascular disease (CVD) and all-cause
mortality, but is inadequately described in patients with schizophrenia. The aim of this study was to evaluate
treadmill VO2peak, CVD risk factors and quality of life (QOL) in patients with schizophrenia (ICD-10, F20-29).
Methods: 33 patients, 22 men (33.7 ± 10.4 years) and 11 women (35.9 ± 11.5 years), were included. Patients
VO2peak were compared with normative VO2peak in healthy individuals from the Nord-Trøndelag Health Study
(HUNT). Risk factors were compared above and below the VO2peak thresholds; 44.2 and 35.1 ml·kg
-1·min
-1 in men
and women, respectively.
Results: VO2peak was 37.1 ± 9.2 ml·kg
-1·min
-1 in men with schizophrenia; 74 ± 19% of normative healthy men (p <
0.001). VO2peak was 35.6 ± 10.7 ml·kg
-1·min
-1 in women with schizophrenia; 89 ± 25% of normative healthy women
(n.s.). Based on odds ratio patients were 28.3 (95% CI = 1.6-505.6) times more likely to have one or more CVD risk
factors if they were below the VO2peak thresholds. VO2peak correlated with the SF-36 physical functioning (r = 0.58),
general health (r = 0.53), vitality (r = 0.47), social function (r = 0.41) and physical component score (r = 0.51).
Conclusion: Men with schizophrenia have lower VO2peak than the general population. Patients with the lowest
VO2peak have higher odds of having one or more risk factors for cardiovascular disease. VO2peak should be regarded
as least as important as the conventional risk factors for CVD and evaluation of VO2peak should be incorporated in
clinical practice.
Background
Patients suffering from schizophrenia have a mortality
risk that is two to three times that of the general popu-
lation and the leading cause of death is cardiovascular
disease (CVD) [1,2]. Although, multifactor causes have
been identified, reduced cardiorespiratory fitness has
probably been overlooked as a risk factor for CVD in
patients with schizophrenia [3].
Cardiorespiratory fitness, measured as peak oxygen
uptake (VO2peak) is a strong predictor of CVD and all-
cause mortality [4,5]. Improvements in VO2peak have
indicated reduced risk of CVD, coronary heart disease
and all cause mortality [5]. VO2peak is often a stronger
predictor of mortality than conventional risk factors for
CVD [6]. McAuley and Blair [7] recently pointed out
reduced cardiorespiratory fitness as a greater health
threat than obesity and suggested that more emphasis
should be put on increasing VO2peak. This might be
especially important considering that higher levels of
VO2peak seems to attenuate or eliminate the increased
health risk associated with obesity [8]. Findings from the
epidemiological Nord-Trøndelag Health Study (the
HUNT Study) demonstrate that physical active people
with a clustering of cardiovascular risk factors appears
to have comparable risk of premature death as inactive
individuals without risk factors [9]. In the same cohort
men with VO2peak below 44.2 ml·kg
-1·min
-1 were eight
times more likely to have a cluster of CVD risk factors,
compared to men above 50.5 ml·kg
-1·min
-1 [10].
Results from the Aerobics Center Longitudional Study
further suggest that people with low VO2peak is
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tional well being [11]. High levels of VO2peak are asso-
ciated with high levels of quality of life (QOL) [12].
Body mass index (BMI) are found inversely related to
QOL in patients with schizophrenia [3] but the relation
between VO2peak and perceived QOL are not evaluated.
Objective measures of VO2peak have rarely been pre-
sented in patients with schizophrenia. The classical
study by Carlson et al. [13] were the first to describe
oxygen uptake in patients with schizophrenia, but many
of their patients did not reach values close to maximal
oxygen uptake. Our research group revealed significant
changes in VO2peak after eight weeks of high aerobic
intensity training in patients with schizophrenia [14].
Recently, Strassnig et al. [3] published measures of oxy-
gen uptake in 117 patients with schizophrenia that were
exceedingly low (4.4 metabolic equivalents ≈ 15.4 ml·kg
-
1·min
-1). This VO2peak value are much lower than the
VO2 required for walking in patients with schizophrenia
[14], and at a level that may indicate a need for heart
transplant in heart failure patients [15].
The primary aim of this study was to evaluate objec-
tively measured VO2peak during walking or running in
men and women with schizophrenia compared to
VO2peak in healthy individuals from the Nord-Trøndelag
Health Study (HUNT). We hypothesized that patients
with schizophrenia had reduced VO2peak compared to
normative healthy individuals. The secondary aim was
to evaluate relationships between VO2peak,r i s kf a c t o r s
for cardiovascular disease, and quality of life.
Methods
Subjects
We included 33 patients, 11 women and 22 men, with
ICD-10 schizophrenia, schizotypal or delusional disor-
ders (F20 to F29) in the study. Patients were in- and
out-patients at a University hospital and had agreed to
take part in exercise interventions studies. All patients
were under antipsychotic medical treatment. 24 patients
were smokers. Exclusion criteria were known coronary
artery disease, known chronic obstructive pulmonary
disease, and not being able to perform physical treadmill
testing and exercise. Patients were examined by a physi-
cian at inclusion to the study and the exclusion criter-
ions were confirmed by medical records.
Assessments
An individualized protocol was applied to measure
VO2peak and peak heart rate (HRpeak), using the Cortex
Metamax II portable metabolic test system (Cortex Bio-
p h y s i kG m b H ,L e i p z i g ,G e r m a n y )a n dt h eP o l a rS 6 1 0 i
heart rate monitor (Polar Electro, Finland), respectively.
The protocol has previously been described in patients
with schizophrenia as well as in healthy individuals [14,16].
The patients were carefully familiarized with the test
procedures and the treadmill when entering the labora-
tory. Warm-up was ten minute walking or running on
the treadmill at an intensity corresponding to 60-70%
HRpeak. The test started from warm-up speed (with
minimum 5% inclination) after which the speed or the
inclination was increased every minute (0.5-1 km·h
-1
and 1-2%, respectively) to a level that brought the
patient to exhaustion. The highest oxygen uptake and
heart rate (HR) recorded during the last minute of the
test were determined as VO2peak and HRpeak, respec-
tively. VO2peak where also presented as ml·kg
-0.75·min
-1
to normalise for the differences in bodyweight between
the patients [17].
We compared the patients VO2peak with age and sex
specific strata from the Nord-Trøndelag Health Study
(the HUNT Study) [10]. The HUNT study is an epide-
miological study of the general population in the neigh-
bouring county to the university hospital. The HUNT
Fitness study tested VO2peak in 4 631 healthy individuals
(20 to 90 years) using mixing chamber gas-analyzer
ergospirometry (Cortex MetaMax II, Cortex, Leipzig,
Germany) and an individualised protocol that has close
resemblance to the protocol used in the present study.
14.1% of the participants reported to be inactive, defined
as no activity or exercising less than once per week. For
each patient with schizophrenia, we estimated a norma-
tive VO2peak, namely the mean value defined in the
HUNT Fitness study strata for the corresponding sex
a n da g e .W et i t l e dt h eV O 2peak estimated from sex and
age strata independent of physical activity level, as
HUNT general. The VO2peak from age and sex strata for
healthy inactive men and women were titled HUNT
inactive. The percent of HUNT general and HUNT
inactive VO2peak was calculated as: (achieved VO2peak ÷
age predicted VO2peak) · 100.
In the HUNT Fitness study men and women below
44.2 ml·kg
-1·min
-1 and 35.1 ml·kg
-1·min
-1, respectively,
were associated with higher cardiovascular risk factor
profile [10]. The same VO2peak values were used as
threshold values when evaluating conventional CVD risk
factors.
Morning fasting blood levels were taken. Serum glu-
cose was analysed using Reflotron Plus system (Roche
Diagnostics, Mannheim, Germany). HDL (high-density-
lipoprotein) cholesterol, total cholesterol and triglyceride
concentrations in serum were measured using a Modu-
lar P chemistry analyzer (Roche Diagnostics, Mannheim,
Germany). LDL cholesterol was calculated using the
Friedewald equation [18]. BP (blood pressure) was mea-
sured using a Maxi-Stabil 3 (Welch Allyn, Jungingen,
Germany). Patients were sitting and had rested for at
least 5 minutes. Risk factors were classified as follows:
hypertension, diastolic pressure ≥ 90 mmHg and/or
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6.0 mmol·L
-1; elevated total cholesterol, > 6.1 mmol·L
-1
in patients < 30 years old, > 6.9 mmol·L
-1 in patients
30-49 years old and > 7.8 mmol·L
-1 in patients ≥ 50
years old; elevated LDL-cholesterol, 4.3 > mmol·L
-1 in
patients < 30 years old, 4.7 > mmol·L
-1 in patients 30-49
years old and > 5.3 mmol·L
-1 in patients ≥ 50 years old;
reduced HDL-cholesterol, < 1.0 mmol·L
-1;e l e v a t e dt r i -
glyceride, > 2.6 mmol·L
-1; obesity, BMI ≥ 30.0 kg·m
-1
[19,20].
The short form (SF-36) was used to assess the physical
health and mental health aspects of health related qual-
ity of life [21]. SF-36 consists of eight sub scores and
can also be divided into a physical component score
(PCS) and mental component score (MCS). 0 reflect the
poorest health whereas 100 reflect the best health.
T h eP o s i t i v ea n dN e g a t i v eS y n d r o m eS c a l e( P A N S S )
was used to evaluate the severity of symptoms of schizo-
phrenia [22]. PANSS constitutes three scales measuring
positive (productive symptoms), negative symptoms
(deficit features) and general severity of illness. A total
of 30 items are evaluated on a likert scale ranging from
1( a b s e n t )t o7( e x t r e m e )a n da d d e du pt oat o t a ls c o r e
as well as the three sub scores. In this study we used
the positive and negative sub scores (7 items each) as
well as the total score (30 items).
Analyses
We used the independent samples T-test to compare
differences between men and women, between patients
below and above the VO2peak thresholds as well as
between measured VO2peak and HUNT general and
HUNT inactive VO2peak. We used the Pearson chi-
square test to detect whethert h e r ew a sas i g n i f i c a n t
association between patients above/below the VO2peak
threshold and prevalence of risk factors. We calculated
the odds ratio for having one or more risk factors in
the patients below threshold. The analysis was adjusted
for age and sex. In multiadjusted analysis we also
adjusted for the potential cofounding effect of
smoking.
We used Pearson r to analyse correlations between
VO2peak (ml·kg
-0.75·min
-1) and each domain of the SF-36.
The significance level (a)w a ss e ta tp<0.05 (2-tailed).
Data are described as mean and standard deviation
(SD), unless otherwise noted. SPSS statistical package,
version 18.0 (SPSS Inc.), was applied to analyse results.
The study was approved by the regional committees
for medical and health research ethics, middle Norway
and conducted according to the Helsinki declaration.
Written informed consent was obtained from all the
included patients after the procedures were fully
explained.
Results
Demographics
Age was 33.7 ± 10.4 years and 35.9 ± 11.5 years in men
and women, respectively. The total PANSS, total posi-
tive PANSS and total negative PANSS score was 65 ±
17, 15 ± 6 and 17 ± 8 in men, and 68 ± 23, 16 ± 6 and
18 ± 8 in women, respectively.
Peak oxygen uptake
The VO2peak for the men and women with schizophre-
nia are presented in Table 1. Individual VO2peak values
are plotted against age as well as normative VO2peak
s t r a t af r o mt h eH U N TF i t n e s ss t u d yi nF i g u r e1 .
VO2peak in the men with schizophrenia was 84 ± 21% of
age predicted HUNT inactive (p < 0.001) and 74 ± 19%
of HUNT general (p < 0.001). The VO2peak in the
women with schizophrenia was not different from
HUNT inactive (101 ± 28%) and HUNT general (89 ±
25%; n.s.). Age predicted VO2peak was 44.5 ± 2.9 in
HUNT inactive men, 50.3 ± 4.1 ml·kg
-1·min
-1 in HUNT
general men, 35.2 ± 1.8 in HUNT inactive women and
40.0 ± 3.2 ml·kg
-1·min
-1 in HUNT general women.
Conventional risk factors
Risk factor assessment was lost in one male patient. Risk
factors were present in 24 of 32 patients and of these
five were above and 19 were below the thresholds.
Among the eight patients without risk factors, six were
above and two were below the thresholds (c
2 =7 . 6 ,d f=
1, p = 0.006). Based on the odds ratio adjusted for age
and sex patients were 24.2 (95% CI = 1.5-505.6) times
more likely to have one or more risk factors if they were
below the VO2peak threshold. When we also adjusted for
smoking the odds ratio was 28.3 (95% CI = 1.6-505.6).
Among the patients below the VO2peak thresholds 10
patients had hypertension, 11 elevated glucose, 12
reduced HDL-cholesterol, 11 elevated triglyceride and
14 had obesity. Above the thresholds 2 patients had
hypertension, 2 elevated glucose and 1 was obese. There
were 8 smokers above the thresholds and 16 below. Dif-
ferences in mean levels are presented in Table 2.
Quality of life
Results from the SF-36 questionnaire and correlations
between SF-36 variables and VO2peak are presented in
Table 3.
Discussion
Peak oxygen uptake
The present results highlight reduced VO2peak as a
major risk factor for CVD in patients suffering from
schizophrenia. The VO2peak was 37.1 ± 9.2 and 35.6 ±
10.7 ml·kg
-1·min
-1 in men and women, respectively.
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assumptions [3,13]. Strassnig et al. [3] reported VO2
values of 18.7 ± 6.8 and 13.4 ± 4.6 ml·kg
-1·min
-1in the
men and women, respectively (mean age of 45.1 ± 10.1
years). These low VO2peak values is to some degree
explained by the high body weight (mean BMI of 36.7 ±
7.5 m·kg
2). However, there are some indications of an
underrating of these patients’ VO2peak. First, the patients
only reached a low peak heart rate (142 ± 21 beats·min
-
1). Secondly, both Carlsson et al. [13] and Strassnig et
al. [3] applied a cycle ergometer test which is known to
depend more on the patients motivation than a tread-
mill test. Patients with schizophrenia terminate cycle
tests already at submaximal work loads, in contrast to
health subjects [23]. Thirdly, subjects tested on a cycle
ergometer achieve 7-16% lower VO2max compared with
a maximal treadmill test, even when HRpeak is not sig-
nificantly different [24,25].
In contrast to Strassnig et al. [3], the present results
demonstrate that the mean VO2peak in the women was
similar to the men with schizophrenia, even though the
age was similar (36 years in women versus 34 years in
Table 1 Individual characteristics from the peak oxygen uptake test
Patient Age BW VO2peak VO2peak VO2peak VE RER HR
nr years Kg L·min
-1 ml·kg
-1 ·min
-1 ml·kg
-0.75 ·min
-1 L·min
-1 Beats ·min
-1
Men
1 21 76.5 3.64 47.6 140.7 126.1 1.07 186
2 21 95.3 3.72 39.1 122.0 107.7 1.09 175
3 24 66.6 3.65 54.9 156.6 138.1 1.19 211
4 25 159.5 4.25 26.6 94.7 134.0 1.19 154
5 25 120.9 3.21 26.5 88.0 115.8 1.09 160
6 26 65.0 3.15 48.5 137.6 100.4 1.22 185
7 26 107.9 4.07 37.7 121.6 126.3 1.23 177
8 27 96.7 3.50 36.1 113.5 102.4 1.11 186
9 27 107.2 3.36 31.3 100.9 94.7 1.04 180
10 28 100.6 2.96 29.4 93.2 69.2 1.00 190
11 29 66.7 2.99 44.8 128.1 121.7 1.13 183
12 31 78.0 3.76 48.2 143.3 118.6 1.41 188
13 31 70.1 3.14 44.8 129.6 106.9 1.10 165
14 37 114.0 3.87 34.0 110.9 109.2 1.10 153
15 40 98.7 2.38 24.1 76.0 65.2 1.00 143
16 41 77.4 3.29 42.0 126.1 110.4 1.21 153
17 41 89.5 3.80 42.5 130.6 105.7 1.22 164
18 41 117.1 3.88 33.1 109.0 118.6 1.06 165
19 45 122.3 3.38 27.7 91.9 125.4 1.08 150
20 47 122.7 2.94 24.0 79.7 89.2 1.00 153
21 50 75.7 3.46 45.7 134.8 90.8 1.08 156
22 58 109.6 3.07 28.1 90.6 91.2 1.07 160
Mean ± SD 33.7 ± 10.4 97.2 ± 24.0 3.43 ± 0.44 37.1 ± 9.2 114.5 ± 22.6 107.6 ± 19.0 1.12 ± 0.10 170 ± 17
Women
1 22 61.7 2.98 48.3 135.4 94.1 1.18 180
2 24 53.3 2.28 42.8 115.6 54.0 0.99 173
3 28 66.4 2.82 42.6 121.2 97.1 1.14 169
4 28 73.5 2.33 31.7 92.8 66.4 1.20 176
5 28 80.3 2.44 30.4 91.0 93.0 1.20 188
6 34 51.6 2.61 50.7 135.6 79.8 1.27 194
7 41 144.5 2.46 17.0 59.0 71.0 1.02 150
8 42 75.5 3.30 43.7 128.8 108.0 1.20 163
9 44 64.9 1.98 30.5 86.6 56.0 1.16 175
10 48 55.5 1.70 30.7 83.6 73.2 1.10 168
11 58 91.8 2.12 23.1 71.5 74.1 1.13 151
Mean ± SD 35.9 ± 11.5 74.5 ± 26.3 2.46 ± 0.46 35.6 ± 10.7 101.9 ± 26.6 78.8 ± 17.4 1.15 ± 0.08 172 ± 14
BW, body weight; VO2peak, peak oxygen uptake; HR, heart rate; VE, total pulmonary ventilation; RER, respiratory exchange ratio; SD, standard deviation
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-1·min
-1
lower VO2peak compared to men at the same age [10].
The mean body weight was 97.2 and 74.5 kg in men
and women, respectively, which partially explain the dif-
ference in VO2peak.
Comparison with healthy individuals
The comparison with normalised VO2peak from the
HUNT Fitness study, confirm our hypothesis that
VO2peak is reduced in men with schizophrenia. The
VO2peak in the women with schizophrenia was almost
identical (101%) to inactive healthy HUNT women.
Even lower VO2peak in men with schizophrenia com-
pared to normative inactive men might suggest that
more than just inactivity contribute the reduced
VO2peak.T h eV O 2peak in the men with schizophrenia is
similar to normative healthy men aged 60-69 years [10].
In other words, the VO2peak in the men with schizo-
phrenia is comparable to healthy men that are about 30
years older. Patients with schizophrenia actually have
15-25 years shorter life expectancy than the general
population [26,27]. It is noteworthy that the VO2peak
presented in the HUNT Fitness study is somewhat
higher than previous described populations with regard
to objectively measured VO2peak [28-31].
Cardiovascular risk
People with reduced VO2peak are consistently being
associated with increased risk of cardiovascular and all-
cause mortality. Kodama et al. [5] found that 3.5 ml·kg
-
1·min
-1 (1 MET) increases were associated with 13% and
15% reductions in all-cause mortality and CVD/coronary
heart disease, respectively. Aspenes et al. [10] found that
5m l · k g
-1·min
-1 lower VO2peak correspond to 56% higher
odds of having a cluster of cardiovascular risk factors.
The comparison of patients with schizophrenia below
and above the VO2peak thresholds suggested by Aspenes
et al. [10] confirm that patients below these thresholds
have higher prevalence of risk factors compared with
patients above the thresholds. Based on the odds ratio
patients were 28.3 times more likely to have one or
more risk factors if they were below the VO2peak thresh-
olds. When comparing mean levels above and below
thresholds, all risk factors, except glucose, was better in
the patients above the thresholds. These findings suggest
a strong connection between the patients VO2peak and
the conventional risk factors for CVD, as confirmed in
other populations [10,32].
Our data are not quite consistent with findings from
US suggesting that especially women with schizophrenia
are at high risk of developing metabolic syndrome [33].
Figure 1 Peak oxygen uptake in patients with schizophrenia and normative healthy men and women. Normative strata are adopted
from the HUNT fitness study [10]. HUNT general strata are age and sex specific strata regardless of physical activity level.
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a and Pearson correlation coefficient between SF-36 items and peak oxygen uptake
b
Women (N = 11) Men (N = 19) All (N = 30)
SF-36 items Mean ± SD r Mean ± SD r Mean ± SD r
Physical function (PF) 76.4 ± 28.1 0.68* 82.6 ± 20.2 0.48* 80.3 ± 23.1 0.58***
Role physical (RP) 56.8 ± 35.5 0.61* 67.1 ± 30.1 0.10 63.3 ± 32.0 0.34
Bodily pain (BP) 77.5 ± 24.7 0.06 73.8 ± 26.1 0.11 75.2 ± 25.2 0.26
General health (GH) 58.1 ± 17.6 0.72* 63.6 ± 19.9 0.42 61.6 ± 19.0 0.53**
Vitality (VT) 52.7 ± 22.8 0.71* 51.8 ± 18.6 0.30 52.2 ± 19.9 0.47*
Social function (SF) 51.1 ± 29.8
† 0.41 74.3 ± 17.4 0.34 65.8 ± 25.9 0.41*
Role emotional (RE) 42.4 ± 33.7
† 0.39 73.7 ± 37.8 0.25 62.2 ± 38.9 0.35
Mental health (MH) 55.3 ± 15.1 0.68* 67.0 ± 16.5 0.08 62.7 ± 16.7 0.34
Physical component (PCS) 49.1 ± 10.3 0.72* 48.2 ± 7.6 0.37 48.6 ± 8.6 0.51**
Mental component (MCS) 36.5 ± 8.4
† 0.52 45.6 ± 10.2 0.16 42.2 ± 10.4 0.34
aPatients with schizophrenia
bml·kg
-0.75·min
-1.
* p < 0.05, **p < 0.005, *** p < 0.001 Pearsons r.
† p < 0.05 compared to men, independent T-test.
Table 2 Characteristics
a in patients below and above the threshold peak oxygen uptake (VO2peak)
b
Men
VO2peak (< 44.2) (n = 15) VO2peak (≥ 44.2) (n = 6) Mean difference (95% CI)
Systolic pressure (mm Hg) 139.4 ± 16.8 125.7 ± 11.0 -13.8 (-29.6 to 2.0)
Diastolic pressure (mm Hg) 87.4 ± 7.0 84.3 ± 5.0 -3.0 (-9.7 to 3.6)
Total cholesterol (mmol·L
-1) 5.2 ± 0.7 4.5 ± 0.5 -0.7 (-1.3 to -0.0)
HDL cholesterol (mmol·L
-1) 1.0 ± 0.3 1.6 ± 0.4 0.5 (0.2 to 0.9)
LDL cholesterol (mmol·L
-1) 3.2 ± 0.6 2.5 ± 0.6 -0.7 (-1.3 to -0.1)
Triglyceride (mmol·L
-1) 2.1 ± 1.1 0.9 ± 0.2 -1.2 (-1.8 to -0.6)
Glucose (mmol·L
-1) 6.4 ± 2.0 5.8 ± 0.6 -0.6 (-2.4 to 1.1)
BMI (kg·m
-2) 33.0 ± 5.5 23.6 ± 2.4 -9.5 (-14.5 to -4.5)
Women
VO2peak (<35.1) (n=6) VO2peak (≥35.1) (n=5)
Systolic pressure (mm Hg) 121.6 ± 7.9 103.8 ± 11.9 -17.8 (-32.6 to -3.0)
Diastolic pressure (mm Hg) 80.8 ± 4.4 68.8 ± 8.8 -12 (-22.1 to -1.9)
Total cholesterol (mmol·L
-1) 5.0 ± 0.7 4.6 ± 1.0 -0.4 (-1.5 to 0.8)
HDL cholesterol (mmol·L
-1) 1.3 ± 0.3 1.8 ± 0.3 0.5 (0.1 to 0.9)
LDL cholesterol (mmol·L
-1) 2.9 ± 0.9 2.5 ± 1.1 -0.4 (-1.8 to 1.0)
Triglyceride (mmol·L
-1) 1.8 ± 0.7 0.8 ± 0.3 -1.0 (-1.7 to -0.3)
Glucose (mmol·L
-1) 6.1 ± 1.5 4.8 ± 0.4 -1.3 (-2.9 to 0.2)
BMI (kg·m
-2) 31.2 ± 10.9 23.6 ± 4.5 -7.5 (-19.5 to 4.4)
All
< threshold
(n = 21)
≥ threshold
(n = 11)
Systolic pressure (mm Hg) 134.7 ± 16.8 115.7 ± 15.7 -19.0 (-31.8 to -6.3)
Diastolic pressure (mm Hg) 85.63 ± 6.9 77.3 ± 10.4 -8.4 (-14.9 to -1.9)
Total cholesterol (mmol·L
-1) 5.1 ± 0.7 4.6 ± 0.7 -0.6 (-1.1 to -0.0)
HDL cholesterol (mmol·L
-1) 1.1 ± 0.3 1.6 ± 0.3 0.5 (0.0 to 0.1)
LDL cholesterol (mmol·L
-1) 3.1 ± 0.7 2.5 ± 0.8 -0.6 (-1.2 to -0.1)
Triglyceride (mmol·L
-1) 2.0 ± 1.0 0.9 ± 0.3 -1.1 (-1.6 to -0.7)
Glucose (mmol·L
-1) 6.3 ± 1.8 5.3 ± 0.7 -1.0 (-2.2 to 0.2)
BMI (kg·m
-2) 32.4 ± 7.5 23.6 ± 3.3 -8.8 (-13.7 to -3.9)
amean ± SD.
b44.2 ml·kg
-1 ·min
-1 in men and 35.1 in women based on the results from Aspenes et al. [10].
HDL, high-density lipoprotein; LDL, low-density lipoprotein; BMI, body mass index.
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in the present study, as VO2peak have been described as
a strong independent predictor of metabolic syndrome
[32].
These results emphasize that evaluation of VO2peak
should be incorporated into routine clinical practice for
risk prediction. The prognostic value of VO2peak is
beyond that predicted from other conventional risk fac-
tors [6,34]. Even in individuals with present risk factors,
the higher levels of VO2peak seem to confer a significant
protective effect [4]. Reduced VO2peak is a modifiable
risk factor, and eight weeks aerobic high intensity inter-
val training has provided significant improvements of
VO2peak both in healthy populations [16] and in patients
with schizophrenia [14]. Furthermore, to reduce the risk
of CVD, the interventions are probably more dependent
on improving VO2peak than increasing physical activity
level alone [35,36].
Quality of life
Our findings of lower SF-36 social function, role emo-
tion and mental component score among women than
among men might reflect a sex difference in the general
population. Lower scores for women than for men have
been identified in normative adults [37]. The gender-
specific correlations between items of SF-36 and
VO2peak suggest major gender differences in self-percep-
tion. Only the correlation with between SF-36 physical
functioning and VO2peak was significant in men, whereas
six correlations with the SF-36 were significant in
women. In all subjects together the VO2peak correlated
with the patient’s perception of physical function, gen-
eral health, vitality, social function, and physical compo-
nent score. With some exceptions, these findings are
consistent with correlations between SF-36 variables and
BMI in patients with schizophrenia [38]. In line with
Strassnig et al. [38] we found a significant correlation
with the physical component score but not the mental
component score, suggesting that reduced VO2peak
mainly is perceived as a physical health problem, not
mental. Contrary, both the mental and physical health
components of QOL are found related to estimated
VO2peak in healthy men [12]. An interesting note is,
however, that the patients with lower VO2peak seemed to
experience lower vitality and social functioning. Seden-
tary people are associated with greater risk of low vital-
ity [39]. QOL are found to improve in a dose dependent
manner in sedentary women when increasing physical
activity level [40].
Limitations
There are some limitations of the study. First, the sam-
ple size is low. Secondly, the patients were included in
the study based on request to take part in exercise
intervention studies. However, all eligible patients at the
department were asked to participate in these studies.
Thirdly, severe ill patients with schizophrenia, with poor
insight to their illness, might have difficulties to evaluate
their perception of QOL.
Conclusions
Men with schizophrenia have lower VO2peak than men
in the general population. Patients with a VO2peak below
44.2 ml·kg
-1·min
-1 (men) and 35.1 ml·kg
-1·min
-1
(women) have higher odds of having one or more risk
factors for cardiovascular disease. Low VO2peak compro-
mise patients’ perceived physical health. VO2peak should
be regarded as least as important as the conventional
risk factors for CVD and evaluation of VO2peak should
be incorporated in clinical practice. Finally, these finding
represent an urging need for developing effective physi-
cal training interventions for patients with
schizophrenia.
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